MYCBP2

E3 ubiquitin-protein ligase MYCBP2 · O75592 · MYCBP2 on Sugi Atlas →

0 patent compounds predicted against MYCBP2, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to MYCBP2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL PHASE2ACTIVE_NOT_RECRUITING
Preliminary Study of Mycograb and Docetaxel in Advanced Breast Cancer PHASE1/PHASE2COMPLETED
EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma PHASE2COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL PHASE1/PHASE2RECRUITING
Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis PHASE2ACTIVE_NOT_RECRUITING
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers PHASE1/PHASE2COMPLETED
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients PHASE2COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas PHASE1COMPLETED
Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer PHASE1ACTIVE_NOT_RECRUITING
Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma EARLY_PHASE1RECRUITING
Establishment of a Prospective Clinical-biological Database nanRECRUITING
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma nanCOMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Genetic Variation in TRAF3IP2 (rs13190932) nanRECRUITING
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING
Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas nanRECRUITING
Study of Proteins in Head and Neck Cancer Cells nanCOMPLETED
Transcripts with Retained H/ACA Box SnoRNA Sequences As Biomarkers for Estrogen Dependence in Lum-B Breast Carcinomas nanACTIVE_NOT_RECRUITING
Value of MicroRNA30a in Philadelphia Positive Leukemic Patients nanUNKNOWN
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical Impact nanUNKNOWN
Inflammatory/Familial Dilated Cardiomyopathy: Is There a Link to Autoimmune Diseases? TP9a nanCOMPLETED
Cytomegalovirus (CMV) MicroRNA Expression in Vivo and Immune Evasion Correlates nanCOMPLETED
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy nanUNKNOWN
DNA Analysis of Tumor Tissue Samples From Patients With Diffuse Brain Stem Glioma nanCOMPLETED
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress nanWITHDRAWN
The Molecular Pathogenesis Study of Cataract nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a MYCBP2 binder may also engage these)

ProteinNameSimilarity
Q7TPH6 1.000 Q7TPH6 →
F1RD40 1.000 F1RD40 →
O88738 0.998 O88738 →
Q9UPV7 0.996 Q9UPV7 →
Q9BVR0 0.996 Q9BVR0 →
Q8BFX3 0.995 Q8BFX3 →
MAP3K13 Mitogen-activated protein kinase kinase kinase 13 0.995 landscape →
Q21920 0.995 Q21920 →
O14715 0.994 O14715 →
Q99666 0.994 Q99666 →
E9Q555 0.994 E9Q555 →
A3KMV1 0.994 A3KMV1 →
Q5MNV8 0.994 Q5MNV8 →
Q8TBC3 0.994 Q8TBC3 →
O61608 0.994 O61608 →
Q8C0P7 0.994 Q8C0P7 →
F5HB62 0.994 F5HB62 →
P03177 0.994 P03177 →
Q92539 0.994 Q92539 →
Q80UK8 0.993 Q80UK8 →
Q1HVD1 0.993 Q1HVD1 →
B9EJV3 0.993 B9EJV3 →
A7MBB4 0.993 A7MBB4 →
Q1LVQ2 0.993 Q1LVQ2 →
Q6ZN28 0.993 Q6ZN28 →
Q18892 0.993 Q18892 →
O43310 0.993 O43310 →
O36371 0.993 O36371 →
Q6IV56 0.993 Q6IV56 →
Q9VB11 0.992 Q9VB11 →